Metallo--lactamase (MBL) inhibitors can restore the function of carbapenem antibiotics and therefore help to treat infections of antibiotic resistant bacteria. In this study, we report novel fragments inhibiting the clinically relevant MBL VIM-2. The fragments were identified from a library of 490 fragments using an orthogonal screening approach based on a Surface Plasmon Resonance (SPR) based assay combined with an enzyme inhibition assay. The identified fragme nts showed IC50 values between 12 and 1500 µM and ligand efficiencies (LE) between 0.48 and 0.23 kcal/mol per heavy atom. For two of the identified fragments, crystal structures in complex with VIM-2 were obtained. The identified fragments represent novel inhibitor scaffolds and are good starting points for the design of potent MBL inhibitors. Furthermore, the established SPR based 2 assay and the screening approach can be adopted to other MBLs and in this way improve the drug discovery process for this important class of drug targets.
INTRODUCTION
The rapid emerging of antibiotic resistant bacteria is a major threat to global public health according to a report released by the World Health Organization (WHO) in 2014 1 . One of the last-line drugs for the treatment of patients infected with antibiotic resistant bacteria are carbapenem antibiotics. Disturbingly, an increasing number of carbapenemases, β-lactamases with a broad hydrolytic capacities to destroy carbapenem antibiotics, are reported 2 . Carbapenemases can be divided into two different groups, metallo--lactamases (MBL) and serine--lactamases (SBL) 3 . For SBLs, the co-administration of SBL inhibitors together with carabapenemen antibiotics has already been proven as a successful strategy to restore their function 4 . Despite the urgent need and the reporting of promising MBL inhibitors [5] [6] [7] [8] [9] , so far there are no clinica lly approved drugs targeting MBL's 10 .
One of the most clinically relevant MBL's is the Verona integron-encoded metallo-β-lacta ma se (VIM-2) 2 . The enzyme was first characterized in Pseudomonas aeruginosa 11 , but has also spread to other bacteria like Enterobacteriaceae 12 . VIM-2 has a broad substrate hydrolysis range, including penicillins, cephalosporins, cephamycins, oxacephamycins, and carbapenems 11 . The enzyme is folded into a / sandwich with two zinc ions in the active site bridged by a hydroxide ion 13 . Due to the high clinically relevance, the wide spread and the broad substrate range, VIM-2 is an important drug target to restore the function of carbapenem antibiotics and the treatment of antibiotic resistant bacteria.
Fragment based drug discovery (FBDD) is proven to have a high potential to identify novel inhibitor scaffolds especially for challenging drug targets. The method is based on identifying small molecule inhibitors with low affinity, which can be linked or further evolved into potent inhibitors. In this way, the chemical space can be explored more efficiently compared to traditio na l high-throughput screenings 14 . Different biochemical assays, e.g. enzymatic assays, and biophysical assays, e.g. NMR spectroscopy, X-ray crystallography, Surface plasmon resonance (SPR) spectroscopy, mass spectrometry and isothermal titration calorimetry have been adopted to the needs of FBDD 14 . A common problem in FBDD are false positive hits caused by Pan Assay
Interference Compounds (PAINS) 15 . Such compounds show an apparent inhibition due to a variety of mechanisms, e.g. influencing assay conditions, interfering with read outs or unspecific binding to the protein surface. The use of an orthogonal screening approach, combining a biophysical and a biochemical assay, is the best way to avoid problems caused by PAINS 14 . Especially SPR based assays have a great potential to identify PAINS and hence are one of the most powerful screening techniques in FBDD [16] [17] [18] . Despite the clear advantage of the technique not only for FBDD, but also for hit to lead optimization, SPR based assays have rarely been used to study MBLs.
In this study, FBDD was used to identify novel inhibitor scaffolds, which have the potential to be further optimized into drug leads for the clinically relevant carbapenemase VIM-2. An SPR based assay was established for the enzyme and validated by studying the interaction with meropenem and captopril. An orthogonal screening approach combining a biophysical SPR based assay with a biochemical inhibition assay was used to screen a library of 490 fragments. 9 fragment specifically inhibiting VIM-2 were identified. For two of the fragments, detailed X-ray crystal structure were obtained. The structures allow identifying interactions crucial for the binding of the fragments.
RESULTS AND DISCUSSION
Expression, purification and characterization of VIM-2. The new His-tagged VIM-2 gene construct was expressed in E. coli and initially purified by immobilized metal ion affinity chromatography (IMAC). The His-tag was removed by cleavage using the tobacco etch virus (TEV) protease and the protein further purified by ion exchange chromatography. Protein identity was confirmed by mass spectroscopy and the protein purity was judged from the SDS-PAGE analyses to be above 95% (data not shown). Around 45 mg pure VIM-2 was yielded from 2 L cell culture.
Nitrocefin is a widely used chromogenic reporter substrate to monitor the activity of MBLs 10 .
An enzyme activity assay based on nitrocefin was used to verify the activity of the purified VIM-2. Furthermore, the assay was used to explore the influence of different buffer conditions suitable for fragment screening and the DMSO concentration on the enzyme activity. Up to 2.5% DMSO, no influence on the enzyme activity was observed (data not shown). For the hydrolysis of nitrocefin, steady-state kinetic parameters Km and kcat were determined in HEPES buffer (pH 7.2) with 34 ± 2 µM and 1170 ± 25 s -1 , respectively ( Figure 1A) . Additionally, the IC50 for the known MBL inhibitor captopril was determined to be 3.5 µM ( Figure 1B) . The values were in accordance with the literature 6, 19 , showing that the chosen HEPES based buffer did not influence the activity of VIM-2 and hence was suitable to be used during the fragment screening.
SPR-based binding studies with meropenem and captopril. SPR based assays are widely used in drug discovery. However, such assays have rarely been used to study -lactamases. We established an SPR based assay for VIM-2, suitable to study the interactions with small molecules.
The immobilization of VIM-2 to the SPR sensor surface was achieved by biotin-streptavid in capturing resulting in a stable surface with an immobilization level of around 1600 response units (RU). To ensure that the protein was active on the surface, the interactions with meropenem and captopril were investigated. Meropenem interacted reversibly with VIM-2, showing a fast association and dissociation ( Figure 2A ). The steady state values were calculated from the sensorgrams and plotted against the concentration. Data were fitted to a 1:1 interaction model and the binding affinity (KD) was calculated with 12 µM. Due to the fast interaction kinetics, it was not possible to determine the association or dissociation constant. The determined KD for meropenem was in a similar range as the Km of 2 µM reported by Docquier et. al. 19 . Captopril bound reversibly to VIM-2 with a clear association and dissociation phase ( Figure 2B ). The sensorgrams could be described by a 1:1 interaction model. The calculated association constant (ka) was 4.2*10 4 M -1 s -1 , the dissociation constant (kd) was 0.025 s -1 and KD was 0.6 µM. The determined KD was in accordance with the IC50 of 3.5 µM determined with enzymatic inhibitio n assay, showing that both assays produced consistent results. From the immobilization level of VIM-2 and the saturation levels reached by meropenem and captopril, it was estimated that around 35% of the immobilized protein were active. Although the signal intensity was in a low range, the interaction with captopril (Mw= 217.3 g/mol) clearly showed that the assay was capable to detect the binding of molecules in the size of fragments.
Screening of the fragment library. The aim of the study was to identify novel fragments inhibiting the metallo--lactamase VIM-2. The used fragment library was purchased from Maybridge (Cambridge, UK) and consisted of 490 fragments. All fragments had a molecular weight below 300, ≤ 3 H-bond acceptors and donors, ≤ 3 rotatable bonds and a clogP ≤ 3.
A common problem in fragment based drug discovery are false positive hits often caused by PAINS 15 . In this study, we choose an orthogonal screening strategy combining a biophysical and a biochemical assay. It has been shown that such combination have high probability to avoid false positive hits 14 . The screening of the library was made in three consecutive steps, starting with a single concentration screening, followed by a concentration series screening and an inhibitio n screening.
The aim of the single concentration screening was to identify potentially binding fragments and to sort out fragments showing no interaction at all with VIM-2. The established SPR based biosensor assay was used to investigate the binding of all fragments at a single concentration of 300 µM. Repeated injections of captopril as positive controls insured that the surface was stable and VIM-2 was active during the whole screening. The screening was repeated two times in reversed sample orders. Sensorgrams were visually inspected to identify fragments inducing a significant signal increase in at least one of the screens. 53 fragments were selected for the concentration series screen.
The aim of the concentration series screen was to identify fragments causing false positive hits.
Since SPR based assays can monitor fragment binding in real time, they have a great potential to identify such fragments 16 . The selected fragments from the single concentration screen were tested at four different concentration (300 µM, 100 µM, 33 µM and 11 µM). Sensorgrams were visually inspected and fragments showing extremely slow dissociation, strong secondary effects or no clear concentration dependency were rejected. Furthermore, for every fragment the theoretical Rmax was calculated according to the signal of the positive control and the molecular weight of the fragment.
Fragments showing at the highest concentration a signal five times higher as the theoretical maximum binding capacity (Rmax) were rejected as promiscuous binders. Rejecting of fragme nts showing undesirable binding properties can result in false negative hits. However, it is unlike ly and an accepted procedure in SPR based fragments screening to avoid problems caused by false positive hits 16-18, 20, 21 . 27 fragments showed a concentration dependent reversible interaction with a KD below 5 mM and a signal range expected for a 1:1 interaction. These fragments were further tested in the enzyme activity assay to determine their inhibition potency.
An SPR based assay gives only information about the binding of a fragment to a protein. Since the place of binding is unknown, it is not clear if such interactions have the ability to reduce the enzyme activity. Therefore, the fragments identified as binders in the single concentratio n screening and the concentration series screening were tested in an enzyme inhibition assay. 9
fragments showed at a concentration of 500 µM an inhibition of VIM-2 by more than 15% against nitrocefin and were hence considered as hits ( were not considered as interesting starting points for the inhibitor design.
Characterization of the fragment hits by determining the K D and the IC 50 . The SPR based assay was used to determine the KD for the 9 fragment hits. All fragments were analyzed in a 1.5 dilution-series starting at 300µM ( Figure 3 ). The steady state values were calculated from the sensorgrams, plotted against the concentration and fitted to an interaction model for a single binding site with a constant Rmax (Table 1) . Fragment 1 and 2 showed the highest KD with 145 µM and 9 µM. These two fragments were also the only fragments showing a clear saturation in the steady state plots. However, it has been shown that steady state plots, also not reaching saturation, are a robust method to estimate KD values 17 .
The enzyme activity assay based on the substrate nitrocefin was used to determine the IC50 values for the fragment hits. For every fragment, the percentage of inhibition was determined in a 2-fold dilution series and plotted against the concentration ( Figure 4 ). The IC50 values were calculated by fitting the data to a one-parameter dose-response curve with a Hill coefficient of 1, a maximum activity of 100% and a minimum activity of 0% (Table 1) . Due to high IC50 values and limited solubility, only parts of the dose-response curves were obtained and full inhibitio n could not be reached for several fragments. However, also in such cases the determined IC50 values can be assumed as good estimations sufficient for evaluating the fragment hits. Fragment 6 induced an increase in enzyme activity at the concentration 750 µM and 1500 µM. This was probably due to unspecific effects and hence the two highest concentrations were removed from the doseresponse plot. Fragment 9 had a yellow color causing a strong background signal at higher concentrations. Therefore, the concentration 750 µM and 1500 µM were removed from the doseresponse plot.
X-ray structures and structure activity relationship (SAR).
To obtain structural informatio n on the binding of the fragment hits, they were soaked into VIM-2 crystals. For fragment 1 and fragment 2, complex structures were obtained clearly showing additional electron density in the active site of VIM-2 ( Figure 6 ).
The complexes crystallized in the C2 space group with two protein molecules in the asymmetr ic unit or in I222 with one protein molecule in the asymmetric unit. Details on the X-ray data collection and refinement statistics are shown in Table 2 . The obtained VIM-2 structures were similar to previous published structures 13, 22 with the typical / sandwich folding and two Zn 2+ ions located in the active site of the enzyme. The first Zn 2+ (Zn1) was coordinated by His116, His118 and His169, whereas the second Zn 2+ (Zn2) was coordinate by Asp120, Cys221 and
His263. Both Zn ions were bridged by a hydroxide ion. A third Zn 2+ (Zn3) was coordinated by
His178 in one molecule, His285 of the symmetry mate and two chloride ions. In structure VIM-2-1, one of the coordinating chloride ions was partially replaced by fragment 1. The Zn3 binding site has been observed before in other VIM-2 structures 13, 22 and is likely a crystallographic artefact.
In the complex structure with fragment 1 and 2, a partial oxidation of Cys221 to a cysteine sulfonate residue (Osc221) was observed. In order to prevent this oxidation, crystals were grown in the presence of 5 mM -mercaptoethanol, 1 mM DTT or 1 mM TCEP. However, in our hands the additives had no influence on the degree of oxidation. To investigate the cause of oxidation further, data were collected at a low intensity beam at an in-house rotating anode radiation source.
The structure showed no signs of oxidation of Cys221 ( Figure 5 ). In contrast, data collected at the high intensity beamline BL14.1 at the BESSY II electron storage ring (Berlin-Adlers ho f, Germany) resulted in a structure with Cys221 completely oxidised to the cysteine sulfonate. Since the crystals used for both data collections were from the same 24 well crystallisation tray and had been grown for a similar amount of days, we suspect that oxidation of Cys221 was due to radiation damage 23, 24 . However, the overall structure of the oxidised and reduced form of VIM-2 were similar, except minor changes in the close environment of Cys221. Similar changes caused by oxidation of Cys221 have been observed before by Garcia-Saez et. al. 13 for VIM-2 and by Borra et. al. for VIM-7 25 and GIM-1 26 .
In the structure VIM-2-1 electron density corresponding to fragment 1 was observed in the active site of both molecules of VIM-2 (chain A and B) in the asymmetric unit ( Figure 6 ). Fragment 1 directly interacted with the two Zn ions in the active site, whereby Zn1 was coordinated by the triazole ring and Zn2 by the thiol group. A positive difference in electron density was observed between the two zinc ions. This positive density was removed by adding a hydroxide ion bridging the two zinc ions. The occupancy for the bridging hydroxide ion was 0.22 and 0.32 (Chain A and B) and for the fragment 0.68 and 0.78 (Chain A and B). Furthermore, the hydroxide ion and fragment 1 were in close contact. This indicates that the observed hydroxide ion is from the unbound native structure. Fragment 1 is already known as an inhibitor for the MBL IMP-1 27 and extensive SAR has been carried out, concluding that the thiol group is crucial for fragment binding, whereas the N-methyl group and the trifluoromethyl group did not influence the affinity 5 .
Although the SAR studies have been carried out with IMP-1, they are in accordance with our VIM-2 crystal structures, showing that the N-methyl group and the trifluoromethyl group form no close interactions with the protein.
The experimental electron density map of structure VIM-2-2 clearly showed the binding of (Figure 7 ). This shows that the fluorine atom was not crucial for the binding affinity.
In accordance with the crystal structure, removing of the carbonyl group (2c), changing the carboxyl group into a methyl ester (2d) or removing of the fluorine-substituted phenyl group (2e) prevents important interactions and hence results in a strong increase of the IC50 values ( Figure 7 ).
Although all fragment hits were soaked into VIM-2 crystals, only for fragment 1 and 2 convincing complex structures were obtained. The fact that no further complex structures were obtained might be explained by short soaking times and the low fragment concentration as well as the lower affinity of the fragments. However, optimisation of these factors was difficult due to the low stability of the crystals in solutions containing DMSO.
Evaluation of the fragment hits. The fragment hits identified in the screening showed a wide structural diversity and to our knowledge, none of them has been reported before as VIM-2 inhibitors. To evaluate the quality of the fragment hits, the ligand efficiency (LE) was calculated ranging from 0.48 to 0.23 kcal/mol per heavy atom (Table 1) . LE is a common metric in FBDD and allows comparing the affinity of fragments corrected for their size. Fragments with a LE higher as 0.3 kcal/mol per heavy atom are normally considered as good starting points for further optimisation 28 . However, LE should not been seen as an absolute criteria and rather as an indicator, which can help to choose fragments most suitable for further optimisation. The fragment based approached used in this study applied an SPR based assay and an enzyme inhibition assay. SPR based assays are widely used in drug discovery, but have rarely been used for -lactamases. To our knowledge, this study is the first report using an SPR based assay to study an MBL. The SPR based assay and thereby the screening approach can easily be adapted to other MBL's and in this way improve the drug discovery process for this important class of drug targets.
The rediscovering of fragment 1 clearly shows that the screening approach established in this study is highly suitable to identify promising starting points for the development of potent inhibitors.
Hence, the approach can be used to identify further interesting fragment hits by screening larger fragment libraries or more specialized libraries, like natural product based libraries or libraries with enhanced 3D characteristics.
EXPERIMENTAL SECTION
General Procedures. Chemicals and solvents were purchased from standard suppliers and used without further purification unless specified different. The fragment 2 analogues 2-benzoylbenzo ic acid (2a), 2-(4-chlorobenzoyl)benzoic acid (2b), 2-benzylbenzoic acid (2c), methyl-2-benzoylbenzoate (2d), 2-acetylbenzoic acid (2e), were purchased from Sigma-Aldrich. Primers were purchased from Sigma-Aldrich. The class B -lactamase numbering system is used throughout this paper for numbering of all residues 31 .
Cloning, Expression and Purification of VIM-2. The blaVIM-2 gene was amplified from
Pseudomonas aeruginosa strain 301-5473 and cloned into the expression vector pET26
(Novagen). The gene sequence coding for residues Val25 to Glu300 of VIM-2 was amplified from the template VIM-2 pET26 using Phusion PCR with the forward primer VIM-2-V25fw (5'-CAT CAC CAT CAC CAT CAC GAA AAC CTG TAT TTC CAG GGA gta gat tct agc gg-3') and the reverse primer VIM-2rev (5'-GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC TTA cta ctc aac gac tga gcg att -3', the TEV protease site is in bold, the 6xHis-tag in italic, gene specific parts in lower-case and the attB site is underlined). The PCR contained 1 x HF buffer, 200 µM deoxynucleoside triphosphate (dNTP) mix, 0.5 µM forward primer, 0.5 µM reverse primer, approximately 100 ng VIM-2 pET26 template, 1 µL (0.02 U) Phusion polymerase and nuclease free water. The amplification started with an initial denaturation at 95°C for 5 min, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s and elongation at 72°C for 45 s, followed by a final extension at 72°C for 5 min. The PCR product was analysed by agarose gel electrophoresis and gel purified using the NucleoSpin Gel and PCR Clean-up kit (MachereyNagel).
After purification, the PCR product was used as a template in a second Phusion PCR conducted under the same conditions as described above. As forward primer attB1-His fw (5'-G GGG AC A AGT TTG TAC AAA AAA GCA GGC TTC GAA GGA GAT AGA ACC ATG CAT CAC CAT CAC CAT CAC -3', the 6xHis-tag is in italic and the attB site is underlined) and as reverse primer VIM-2rev were used. The PCR product was analysed by agarose gel electrophoresis, purified and The cell pellets from 2 L culture were solubilized in 70 mL buffer A (50 mM Tris/HCl pH 7.2, 150 mM NaCl, 100 µM ZnCl2 and SIGMAFAST™ Protease Inhibitor Cocktail) and lysed by sonication, followed by a centrifugation (25400 g, 4°C, 30 min) to remove insolubilities. The supernatant was applied to a 5 mL HisTrap HP column (GE Healthcare) and washed with 5%
buffer B (50 mM Tris/HCl pH 7.2, 150 mM NaCl, 100 µM ZnCl2 and 500 mM imidazole). Bound protein was eluted using a linear gradient from 5% to 100% buffer B. Fractions containing VIM-2 were identified by SDS-PAGE and pooled. In-house produced His-tagged TEV protease 32 was added to the pooled fractions in a molecular ratio 1:10 and dialysed over night at 4°C against buffer A using a 10 kDa cut-off SnakeSkin dialyse tubing (Thermo Scientific). To remove contaminatio n, uncleaved protein and the His-tagged TEV protease, a second His Trap purification was performed as described above. The flow through was collected and dialysed against 50 mM Tris/HCl pH 7.2 and 100 µM ZnCl2. For final purification, the protein was applied to a 5 mL anion exchange Hitrap Q column and eluted with linear gradient across 0 to 1 M NaCl.
Enzyme activity and inhibition. Enzyme activity measurements were carried out at 25°C using a SpectraMax M2 e (Molecular Devices) and 96-well plates. The buffer used in all experime nts consisted of 100 mM HEPES, 150 mM NaCl, pH 7.2, 100 µM ZnCl2 and 0.005% surfactant P-20, 2.5% DMSO, 20 µg/mL BSA. Data were analyzed using the software SoftMax Pro 5.2 (Molecular Devices) and GraphPad Prism 5 (GraphPad Software). All measurements were repeated at least three times.
Steady state measurements were used to determine Km and kcat for nitrocefin (Calbiochem). The substrate was dissolved in buffer in a 2-fold dilution series starting from 250 µM. The enzymatic reaction was started by adding VIM-2 to a final concentration of 75 pmol. Cleavage of the substrate was followed by measuring the absorption at 482 nm every 17 s over 20 min. The initial velocity was determined and, Km and kcat were calculated from the resulting Michaelis-Menten plot.
The inhibition of VIM-2 by the fragments select during the SPR screening was determined using the enzymatic nitrocefin assay. Fragments were dissolved in buffer, mixed with VIM-2 and incubated for 5 min. The enzymatic reaction was started by adding nitrocefin to a final concentration of 3 µM. The final fragment concentration was 500 µM and the final enzyme concentration was 75 pmol. The absorption was measured at 482 nm every 17 s over 20 min. The initial velocity was determined and the percentage of enzyme inhibition was calculated in relation to a reference without fragment.
To determine the IC50 values, the inhibition of each fragment was determined as described above for a 2-fold dilution series starting at 1.5 mM. The inhibition values were plotted against the fragment concentration and the IC50 values were calculated fitting the data to a dose-response curve with constant top plateau (100%), a constant bottom plateau (0%) and a constant Hill slope of -1.
Fragment library. The library contained 490 fragments selected from the Ro3 library from Maybridge (Cambridge, UK). All fragments in the library had a clogP ≤ 3, the number of H-bond acceptors and donors was ≤ 3 and the number of rotatable bonds was ≤ 3. The purity of the fragments was ≥ 95%. The molecular weights of the fragments ranged between 80 and 300 Da.
Fragments were dissolved at 150 mM in 100% DMSO and stored at 4°C.
SPR-based interaction analyses.
Experiments were performed at 25°C using a Biacore T200
(GE Healthcare). The running buffer consisted of 100 mM HEPES pH 7.2, 150 mM NaCl, 100 µM ZnCl2, 0.005% surfactant P-20 and 2.5% DMSO. For data analyses, the Biacore T200 evaluatio n software 2.0 (GE Healthcare) was used. All sensorgrams were reference and blank subtracted.
Running buffer was used for blank injections and bulk effects were corrected using solvent correction.
VIM-2 was immobilized using streptavidin-biotin capturing. For the biotinylation, VIM-2 was mixed in a 1:1 molar ratio with biotinamidohexanoic acid N-hydroxysuccinimide ester (SigmaAldrich) in 0.1 M phosphate buffer pH 7.2 and incubated at room temperature for 30 min.
Unreacted biotinamidohexanoic acid N-hydroxysuccinimide ester was removed using an Amicon ultra centrifugal filter (Merck Killipore Ltd.) with a molecular cut off of 10 kDa.
Streptavidin (Sigma-Aldrich) was covalently coupled to a CM5 chip (GE Healthcare) by standard amine coupling. Therefore, streptavidin was dissolved in 10 mM Na-Acetate pH 4.8 at a concentration of 300 µg/mL and injected for 1200 s. Afterwards, biotinylated VIM-2 was injected for 240 s at a flow rate of 5 µL/min. The surface was blocked by injecting running buffer containing 0.2 µg/mL biotin (Sigma-Aldrich). A reference surface was prepared by immobilizing streptavidin directly followed by blocking with biotin. For the single concentration screen, all fragments were diluted to 300 µM in running buffer and injected for 30 s. The dissociation was followed for 15 s. For every 12 th fragment, a positive control containing 300 µM captopril and a blank were injected. Sensorgrams were visually inspected and fragments inducing a reversible signal increase above the noise level were selected for the secondary screening. The whole fragment library was screened two times in different orders.
Fragments selected in the single concentration screening were tested again in a concentratio n series of 900 µM, 300 µM, 100 µM, 33 µM and 11 µM. The fragments were diluted in running buffer and injected for 30 s. Table 2 . The data set were integrated, scaled and truncated using XDS 34 , POINTLESS and AIMLESS 35, 36 . The phase problem was solved by molecular replacement with PHASER 37 using a VIM-2 structure (PDB ID:1KO3). Final structures were obtained by several refine me nt cycles using PHENIX 38 . Between the refinement cycles, manual model building in WinCoot 39 was used to optimize the model according to the 2F0 -FC and F0 -FC electron density maps.
Translation / Libration / Screw (TLS) parameters were used in the refinement process. Zn and Cl ions were anisotropically refined. Five percent of the X-ray data were used for R-free cross validation. The PyMOL Molecular Graphics System, Version 1.4.1 Schrödinger, LLC was used to generate illustrations. LIGPLOT 40 was used to visualize interaction. Table 1 . Molecular structure, binding affinity (KD), inhibition constant (IC50) and ligand efficie nc y (LE) for the identified fragment hits. Table 2 . X-ray data collection and refinement statistics for VIM-2-NAT, VIM-2-OX, VIM-2-1 and VIM-2-2 a Logarithmic values and standard deviations are reported in the supporting material. b Ligand efficie ncies were calculated as LE = (-R*T*lnKD)/(number of heavy atoms) and are reported in kcal/mol per heavy atom 
TABLES

Accession codes.
Coordinates and structure factors of VIM-2-NAT, VIM-2-OX, VIM-2-1 and VIM-2-2 have all been deposited in the Protein Data Bank with accession numbers 5ACU, 5ACV, 5ACW and 5ACX.
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